|ID||Components||Size (96 tests)||Size (480 tests)|
|PK801-213||Human CTLA-4||15 μg||60 μg|
|PK802-213||Biotinylated anti-CTLA-4 antibody||10 μg||10 μg|
|PK803-213||Streptavidin-HRP||5 μg||10 μg|
|PK804-213||Anti-CTLA-4 antibody||30 μg||30 μg|
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development.
CTLA-4 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Yervoy®. Many investigational anti-CTLA-4 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
The enclosed ELISA assay kit for anti-CTLA-4 h-mAb in mouse serum is based on an enzyme immunoassay (ELISA) between recombinant CTLA-4 protein (ECD) and a biotinylated anti-CTLA-4 monoclonal antibody. The method employs the principle of competitive ELISA, allowing quantification of monoclonal anti-CTLA-4 antibodies in mouse serum.
The assay only involves the following steps:
1. Coat the plate with human CTLA-4;
2. Add the mixture of your sample and biotinylated anti-CTLA-4 antibody;
3. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate;
4. Record the OD readings and analyze the serum concentration.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
There is no requirement for the species and subtype of the antibody.
There is no longer a need to generate anti-drug antibodies for PK studies.
The use of the biotinylated antibody in the competitive ELISA significantly alleviates the issue of background noise issue that often occurs in traditional ELISA method.
Upon receipt, please store all items at -20℃.
After reconstitution, the stock solution should be kept at -80℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 6 months in lyophilized state;
-80℃ for 4 months under sterile conditions after reconstitution.
Inhibition of CTLA-4: biotinylated anti-CTLA-4 antibody binding by an anti-CTLA-4 antibody.
Serial dilutions of the Therapeutic Anti-CTLA-4 Antibody (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL) was added into CTLA-4: Biotinylated Anti-CTLA-4 Antibody binding reactions.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.